From: Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
Survive Additional t (years) from Week 12
+ 20%
−10%
−30%
Sensitivity
PPV
Sensitivitya
PPVb
1
92.7%
82.6%
65.4%
87.1%
48.6%
91.0%
2
93.8%
66.2%
71.2%
75.6%
55.3%
82.8%
3
94.9%
57.6%
76.0%
69.1%
60.8%
77.7%